Can We Use COVID-19 To Transition Towards A Greener, Healthier Future? – Climate Experts Weigh In 27/04/2020 Svĕt Lustig Vijay, Tsering Lhamo & Zixuan Yang “I am not celebrating the fact that people can see the Himalayas or that the air quality is better in Madrid coming out of this virus, but what might come out of it is an awareness of how much human beings have contributed to the ongoing damage to people’s lungs, to our ability to drink […] Continue reading -> Over 30 Antiviral Drugs Being Tested Against Novel Coronavirus – As WHO Convenes Global Innovation Forum 10/02/2020 Elaine Ruth Fletcher “We all have a vested interest to stop this epidemic,” says Thomas Cueni, Director General of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). As WHO on Tuesday convenes a Global Research & Innovation Forum to rapidly ramp up R&D, Cueni spoke with Health Policy Watch about what he describes as “the extraordinary willingness […] Continue reading -> Mental Health – Among The ‘Most Neglected’ Of Neglected Tropical Disease Issues, Says DNDi Scientist 10/01/2020 Grace Ren Neglected tropical diseases (NTDs) can lead to physical disfiguration, stress and stigmatization, which leave lifelong impacts on the mental health of many of those infected, even after the disease itself is cured. As the health community prepares to mark the first-ever World NTD Day on 30 January, Nathalie Strub-Wourgaft, director of Neglected Tropical Diseases at […] Continue reading -> Europe’s Gastein Forum: ‘Healthy Disruption’ To Tackle Inequalities, Promote Well-Being 29/09/2019 Elaine Ruth Fletcher The 2019 European Health Forum (Gastein) opens Wednesday under this year’s theme: “A Healthy Dose of Disruption.” The three-day Forum will explore ways in which Europe can transform health systems into levers of good health and well-being, guided by the aspirations of the recent UN declaration on Universal Health Coverage. Since its foundation in 1998, […] Continue reading -> How To Fix The Medical R&D Model 14/08/2019 David Branigan Fifa Rahman, Unitaid NGO Delegation board member and PhD Candidate at the University of Leeds, moderated a panel at the recent IAS Conference on HIV Science in Mexico entitled “How To Fix Our Medical R&D Model: A Spotlight On TB Treatment.” The panel featured speakers from Médecins Sans Frontières’ (MSF/Doctors Without Borders) Access Campaign, Drugs […] Continue reading -> Making Tough Vaccine Choices Amidst The Ebola Public Health Emergency 24/07/2019 Editorial team WHO’s declaration of the Ebola outbreak in the Democratic Republic of the Congo (DRC) a Public Health Emergency of International Concern has been shadowed by growing questions over vaccine strategy in a crisis that has dragged on for over a year, and now threatens to spread across borders. Until now, a ring vaccination strategy focusing […] Continue reading -> Interview With Seth Berkley, CEO Of Gavi, The Vaccine Alliance 11/06/2019 William New A medical doctor and epidemiologist, Dr Seth Berkley joined Gavi, the Vaccine Alliance, as its CEO in August 2011. Under his leadership, Gavi reached the milestone in 2015 of more than half a billion children vaccinated in the world’s 73 poorest countries. In the same year, Berkley led Gavi to its second successful replenishment, raising […] Continue reading -> Using Policy Levers To Reduce Sugary Drink Consumption 05/04/2019 Elaine Ruth Fletcher The global health organisation Vital Strategies has become a leading actor in the worldwide battle against obesity, which affects 2 billion people globally. Building on its tradition of working to cut tobacco consumption and traffic injuries, the organisation tackled sugary drink consumption as a flagship issue for policy change. While the famous 2013 “soda ban” […] Continue reading -> Access To Essential Medicines – Charles Gore Speaks About MPP’s Expanding Role 25/03/2019 William New Charles Gore took over the role of Executive Director at the Medicines Patent Pool in July 2018, just after its board decided to greatly expand its mandate into essential medicines. Nine months into his term, IP-Watch’s William New talked with him about his role and how the expansion is going. Continue reading -> Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Over 30 Antiviral Drugs Being Tested Against Novel Coronavirus – As WHO Convenes Global Innovation Forum 10/02/2020 Elaine Ruth Fletcher “We all have a vested interest to stop this epidemic,” says Thomas Cueni, Director General of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). As WHO on Tuesday convenes a Global Research & Innovation Forum to rapidly ramp up R&D, Cueni spoke with Health Policy Watch about what he describes as “the extraordinary willingness […] Continue reading -> Mental Health – Among The ‘Most Neglected’ Of Neglected Tropical Disease Issues, Says DNDi Scientist 10/01/2020 Grace Ren Neglected tropical diseases (NTDs) can lead to physical disfiguration, stress and stigmatization, which leave lifelong impacts on the mental health of many of those infected, even after the disease itself is cured. As the health community prepares to mark the first-ever World NTD Day on 30 January, Nathalie Strub-Wourgaft, director of Neglected Tropical Diseases at […] Continue reading -> Europe’s Gastein Forum: ‘Healthy Disruption’ To Tackle Inequalities, Promote Well-Being 29/09/2019 Elaine Ruth Fletcher The 2019 European Health Forum (Gastein) opens Wednesday under this year’s theme: “A Healthy Dose of Disruption.” The three-day Forum will explore ways in which Europe can transform health systems into levers of good health and well-being, guided by the aspirations of the recent UN declaration on Universal Health Coverage. Since its foundation in 1998, […] Continue reading -> How To Fix The Medical R&D Model 14/08/2019 David Branigan Fifa Rahman, Unitaid NGO Delegation board member and PhD Candidate at the University of Leeds, moderated a panel at the recent IAS Conference on HIV Science in Mexico entitled “How To Fix Our Medical R&D Model: A Spotlight On TB Treatment.” The panel featured speakers from Médecins Sans Frontières’ (MSF/Doctors Without Borders) Access Campaign, Drugs […] Continue reading -> Making Tough Vaccine Choices Amidst The Ebola Public Health Emergency 24/07/2019 Editorial team WHO’s declaration of the Ebola outbreak in the Democratic Republic of the Congo (DRC) a Public Health Emergency of International Concern has been shadowed by growing questions over vaccine strategy in a crisis that has dragged on for over a year, and now threatens to spread across borders. Until now, a ring vaccination strategy focusing […] Continue reading -> Interview With Seth Berkley, CEO Of Gavi, The Vaccine Alliance 11/06/2019 William New A medical doctor and epidemiologist, Dr Seth Berkley joined Gavi, the Vaccine Alliance, as its CEO in August 2011. Under his leadership, Gavi reached the milestone in 2015 of more than half a billion children vaccinated in the world’s 73 poorest countries. In the same year, Berkley led Gavi to its second successful replenishment, raising […] Continue reading -> Using Policy Levers To Reduce Sugary Drink Consumption 05/04/2019 Elaine Ruth Fletcher The global health organisation Vital Strategies has become a leading actor in the worldwide battle against obesity, which affects 2 billion people globally. Building on its tradition of working to cut tobacco consumption and traffic injuries, the organisation tackled sugary drink consumption as a flagship issue for policy change. While the famous 2013 “soda ban” […] Continue reading -> Access To Essential Medicines – Charles Gore Speaks About MPP’s Expanding Role 25/03/2019 William New Charles Gore took over the role of Executive Director at the Medicines Patent Pool in July 2018, just after its board decided to greatly expand its mandate into essential medicines. Nine months into his term, IP-Watch’s William New talked with him about his role and how the expansion is going. Continue reading -> Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Mental Health – Among The ‘Most Neglected’ Of Neglected Tropical Disease Issues, Says DNDi Scientist 10/01/2020 Grace Ren Neglected tropical diseases (NTDs) can lead to physical disfiguration, stress and stigmatization, which leave lifelong impacts on the mental health of many of those infected, even after the disease itself is cured. As the health community prepares to mark the first-ever World NTD Day on 30 January, Nathalie Strub-Wourgaft, director of Neglected Tropical Diseases at […] Continue reading -> Europe’s Gastein Forum: ‘Healthy Disruption’ To Tackle Inequalities, Promote Well-Being 29/09/2019 Elaine Ruth Fletcher The 2019 European Health Forum (Gastein) opens Wednesday under this year’s theme: “A Healthy Dose of Disruption.” The three-day Forum will explore ways in which Europe can transform health systems into levers of good health and well-being, guided by the aspirations of the recent UN declaration on Universal Health Coverage. Since its foundation in 1998, […] Continue reading -> How To Fix The Medical R&D Model 14/08/2019 David Branigan Fifa Rahman, Unitaid NGO Delegation board member and PhD Candidate at the University of Leeds, moderated a panel at the recent IAS Conference on HIV Science in Mexico entitled “How To Fix Our Medical R&D Model: A Spotlight On TB Treatment.” The panel featured speakers from Médecins Sans Frontières’ (MSF/Doctors Without Borders) Access Campaign, Drugs […] Continue reading -> Making Tough Vaccine Choices Amidst The Ebola Public Health Emergency 24/07/2019 Editorial team WHO’s declaration of the Ebola outbreak in the Democratic Republic of the Congo (DRC) a Public Health Emergency of International Concern has been shadowed by growing questions over vaccine strategy in a crisis that has dragged on for over a year, and now threatens to spread across borders. Until now, a ring vaccination strategy focusing […] Continue reading -> Interview With Seth Berkley, CEO Of Gavi, The Vaccine Alliance 11/06/2019 William New A medical doctor and epidemiologist, Dr Seth Berkley joined Gavi, the Vaccine Alliance, as its CEO in August 2011. Under his leadership, Gavi reached the milestone in 2015 of more than half a billion children vaccinated in the world’s 73 poorest countries. In the same year, Berkley led Gavi to its second successful replenishment, raising […] Continue reading -> Using Policy Levers To Reduce Sugary Drink Consumption 05/04/2019 Elaine Ruth Fletcher The global health organisation Vital Strategies has become a leading actor in the worldwide battle against obesity, which affects 2 billion people globally. Building on its tradition of working to cut tobacco consumption and traffic injuries, the organisation tackled sugary drink consumption as a flagship issue for policy change. While the famous 2013 “soda ban” […] Continue reading -> Access To Essential Medicines – Charles Gore Speaks About MPP’s Expanding Role 25/03/2019 William New Charles Gore took over the role of Executive Director at the Medicines Patent Pool in July 2018, just after its board decided to greatly expand its mandate into essential medicines. Nine months into his term, IP-Watch’s William New talked with him about his role and how the expansion is going. Continue reading -> Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Europe’s Gastein Forum: ‘Healthy Disruption’ To Tackle Inequalities, Promote Well-Being 29/09/2019 Elaine Ruth Fletcher The 2019 European Health Forum (Gastein) opens Wednesday under this year’s theme: “A Healthy Dose of Disruption.” The three-day Forum will explore ways in which Europe can transform health systems into levers of good health and well-being, guided by the aspirations of the recent UN declaration on Universal Health Coverage. Since its foundation in 1998, […] Continue reading -> How To Fix The Medical R&D Model 14/08/2019 David Branigan Fifa Rahman, Unitaid NGO Delegation board member and PhD Candidate at the University of Leeds, moderated a panel at the recent IAS Conference on HIV Science in Mexico entitled “How To Fix Our Medical R&D Model: A Spotlight On TB Treatment.” The panel featured speakers from Médecins Sans Frontières’ (MSF/Doctors Without Borders) Access Campaign, Drugs […] Continue reading -> Making Tough Vaccine Choices Amidst The Ebola Public Health Emergency 24/07/2019 Editorial team WHO’s declaration of the Ebola outbreak in the Democratic Republic of the Congo (DRC) a Public Health Emergency of International Concern has been shadowed by growing questions over vaccine strategy in a crisis that has dragged on for over a year, and now threatens to spread across borders. Until now, a ring vaccination strategy focusing […] Continue reading -> Interview With Seth Berkley, CEO Of Gavi, The Vaccine Alliance 11/06/2019 William New A medical doctor and epidemiologist, Dr Seth Berkley joined Gavi, the Vaccine Alliance, as its CEO in August 2011. Under his leadership, Gavi reached the milestone in 2015 of more than half a billion children vaccinated in the world’s 73 poorest countries. In the same year, Berkley led Gavi to its second successful replenishment, raising […] Continue reading -> Using Policy Levers To Reduce Sugary Drink Consumption 05/04/2019 Elaine Ruth Fletcher The global health organisation Vital Strategies has become a leading actor in the worldwide battle against obesity, which affects 2 billion people globally. Building on its tradition of working to cut tobacco consumption and traffic injuries, the organisation tackled sugary drink consumption as a flagship issue for policy change. While the famous 2013 “soda ban” […] Continue reading -> Access To Essential Medicines – Charles Gore Speaks About MPP’s Expanding Role 25/03/2019 William New Charles Gore took over the role of Executive Director at the Medicines Patent Pool in July 2018, just after its board decided to greatly expand its mandate into essential medicines. Nine months into his term, IP-Watch’s William New talked with him about his role and how the expansion is going. Continue reading -> Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
How To Fix The Medical R&D Model 14/08/2019 David Branigan Fifa Rahman, Unitaid NGO Delegation board member and PhD Candidate at the University of Leeds, moderated a panel at the recent IAS Conference on HIV Science in Mexico entitled “How To Fix Our Medical R&D Model: A Spotlight On TB Treatment.” The panel featured speakers from Médecins Sans Frontières’ (MSF/Doctors Without Borders) Access Campaign, Drugs […] Continue reading -> Making Tough Vaccine Choices Amidst The Ebola Public Health Emergency 24/07/2019 Editorial team WHO’s declaration of the Ebola outbreak in the Democratic Republic of the Congo (DRC) a Public Health Emergency of International Concern has been shadowed by growing questions over vaccine strategy in a crisis that has dragged on for over a year, and now threatens to spread across borders. Until now, a ring vaccination strategy focusing […] Continue reading -> Interview With Seth Berkley, CEO Of Gavi, The Vaccine Alliance 11/06/2019 William New A medical doctor and epidemiologist, Dr Seth Berkley joined Gavi, the Vaccine Alliance, as its CEO in August 2011. Under his leadership, Gavi reached the milestone in 2015 of more than half a billion children vaccinated in the world’s 73 poorest countries. In the same year, Berkley led Gavi to its second successful replenishment, raising […] Continue reading -> Using Policy Levers To Reduce Sugary Drink Consumption 05/04/2019 Elaine Ruth Fletcher The global health organisation Vital Strategies has become a leading actor in the worldwide battle against obesity, which affects 2 billion people globally. Building on its tradition of working to cut tobacco consumption and traffic injuries, the organisation tackled sugary drink consumption as a flagship issue for policy change. While the famous 2013 “soda ban” […] Continue reading -> Access To Essential Medicines – Charles Gore Speaks About MPP’s Expanding Role 25/03/2019 William New Charles Gore took over the role of Executive Director at the Medicines Patent Pool in July 2018, just after its board decided to greatly expand its mandate into essential medicines. Nine months into his term, IP-Watch’s William New talked with him about his role and how the expansion is going. Continue reading -> Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Making Tough Vaccine Choices Amidst The Ebola Public Health Emergency 24/07/2019 Editorial team WHO’s declaration of the Ebola outbreak in the Democratic Republic of the Congo (DRC) a Public Health Emergency of International Concern has been shadowed by growing questions over vaccine strategy in a crisis that has dragged on for over a year, and now threatens to spread across borders. Until now, a ring vaccination strategy focusing […] Continue reading -> Interview With Seth Berkley, CEO Of Gavi, The Vaccine Alliance 11/06/2019 William New A medical doctor and epidemiologist, Dr Seth Berkley joined Gavi, the Vaccine Alliance, as its CEO in August 2011. Under his leadership, Gavi reached the milestone in 2015 of more than half a billion children vaccinated in the world’s 73 poorest countries. In the same year, Berkley led Gavi to its second successful replenishment, raising […] Continue reading -> Using Policy Levers To Reduce Sugary Drink Consumption 05/04/2019 Elaine Ruth Fletcher The global health organisation Vital Strategies has become a leading actor in the worldwide battle against obesity, which affects 2 billion people globally. Building on its tradition of working to cut tobacco consumption and traffic injuries, the organisation tackled sugary drink consumption as a flagship issue for policy change. While the famous 2013 “soda ban” […] Continue reading -> Access To Essential Medicines – Charles Gore Speaks About MPP’s Expanding Role 25/03/2019 William New Charles Gore took over the role of Executive Director at the Medicines Patent Pool in July 2018, just after its board decided to greatly expand its mandate into essential medicines. Nine months into his term, IP-Watch’s William New talked with him about his role and how the expansion is going. Continue reading -> Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Interview With Seth Berkley, CEO Of Gavi, The Vaccine Alliance 11/06/2019 William New A medical doctor and epidemiologist, Dr Seth Berkley joined Gavi, the Vaccine Alliance, as its CEO in August 2011. Under his leadership, Gavi reached the milestone in 2015 of more than half a billion children vaccinated in the world’s 73 poorest countries. In the same year, Berkley led Gavi to its second successful replenishment, raising […] Continue reading -> Using Policy Levers To Reduce Sugary Drink Consumption 05/04/2019 Elaine Ruth Fletcher The global health organisation Vital Strategies has become a leading actor in the worldwide battle against obesity, which affects 2 billion people globally. Building on its tradition of working to cut tobacco consumption and traffic injuries, the organisation tackled sugary drink consumption as a flagship issue for policy change. While the famous 2013 “soda ban” […] Continue reading -> Access To Essential Medicines – Charles Gore Speaks About MPP’s Expanding Role 25/03/2019 William New Charles Gore took over the role of Executive Director at the Medicines Patent Pool in July 2018, just after its board decided to greatly expand its mandate into essential medicines. Nine months into his term, IP-Watch’s William New talked with him about his role and how the expansion is going. Continue reading -> Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Using Policy Levers To Reduce Sugary Drink Consumption 05/04/2019 Elaine Ruth Fletcher The global health organisation Vital Strategies has become a leading actor in the worldwide battle against obesity, which affects 2 billion people globally. Building on its tradition of working to cut tobacco consumption and traffic injuries, the organisation tackled sugary drink consumption as a flagship issue for policy change. While the famous 2013 “soda ban” […] Continue reading -> Access To Essential Medicines – Charles Gore Speaks About MPP’s Expanding Role 25/03/2019 William New Charles Gore took over the role of Executive Director at the Medicines Patent Pool in July 2018, just after its board decided to greatly expand its mandate into essential medicines. Nine months into his term, IP-Watch’s William New talked with him about his role and how the expansion is going. Continue reading -> Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Access To Essential Medicines – Charles Gore Speaks About MPP’s Expanding Role 25/03/2019 William New Charles Gore took over the role of Executive Director at the Medicines Patent Pool in July 2018, just after its board decided to greatly expand its mandate into essential medicines. Nine months into his term, IP-Watch’s William New talked with him about his role and how the expansion is going. Continue reading -> Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Médecins Sans Frontières On Drug Prices – You Can’t Negotiate Blindfolded 27/02/2019 Elaine Ruth Fletcher Katy Athersuch, Médecins Sans Frontières (MSF) Senior Policy Advisor – Medical Innovation & Access, spoke to Health Policy Watch about the recent proposal by Italy’s Minister of Health, Giulia Grillo, for a World Health Assembly resolution on transparency in drug pricing (Health Policy Watch 18 February). The far-reaching proposal asks countries to require disclosure by pharmaceutical companies of their R&D and, manufacturing costs, and public subsidies received, at the time a drug is registered. The resolution would also strengthen WHO’s role in global monitoring and assessment of available data on the costs and pricing of essential medicines. This is the first in a series of Q&As on the issue, looking towards April’s Fair Pricing Forum, where WHO member states will convene in South Africa, followed by the annual World Health Assembly in May. Continue reading -> Posts navigation Older postsNewer posts